Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials

Published:2016-07-13 Issue:10 Volume:18 Page:1045-1049
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yoon Kun-Ho¹,Nishimura Rimei²,Lee Jisoo³,Crowe Susanne³,Salsali Afshin⁴,Hach Thomas³,Woerle Hans J.³

Affiliation:

1. Seoul St. Mary's Hospital; The Catholic University of Korea School of Medicine; Seoul Korea

2. Jikei University School of Medicine; Tokyo Japan

3. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

4. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield Connecticut USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12699/fullpdf

Reference16 articles.

1. Global estimates of diabetes prevalence for 2013 and projections for 2035;Guariguata;Diabetes Res Clin Pract,2014

2. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables;Ji;BMC Public Health,2013

3. Comprehensive risk assessments of diabetic patients from seven Asian countries: The Joint Asia Diabetes Evaluation (JADE) program;So;J Diabetes,2011

4. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial;Roden;Lancet Diabetes Endocrinol,2013

5. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Häring;Diabetes Care,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

2. Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations;Journal of Diabetes Investigation;2022-10-19

3. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease;Diabetes, Obesity and Metabolism;2022-02-09

4. Healthcare resource utilization in patients treated with empagliflozin in East Asia;Journal of Diabetes Investigation;2022-01-11

5. Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects;Diabetes, Obesity and Metabolism;2022-01-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3